Kanwal Abhinav, Banerjee Sanjay K
Division of Pharmacology, Indian Institute of Chemical Technology, Hyderabad-500607, India.
Pharm Pat Anal. 2013 Jan;2(1):77-91. doi: 10.4155/ppa.12.78.
Inhibiting sodium-glucose co-transporters (SGLT1/SGLT2), which have a key role in the absorption of glucose in the kidney and/or GI tract has been proposed as a novel therapeutic strategy for diabetes. Thus, screening and patenting of chemical compounds for SGLT1/SGLT2 gets more importance in the development of new drugs in diabetes. Several companies are developing SGLT inhibitors, some of which are now in various stages of clinical development. Some molecules in the pipeline, including dapagliflozin, canagliflozin, ASP1941, BI10773, LX4211, RG7201 and TS071, are at various stages of drug development. This patent review presents the overall progress carried out in the development of SGLT inhibitors over the last decade with the active participation of various pharmaceutical companies. This class of drug is anticipated to have a large impact on diabetes field and predicting to attain a blockbuster status.
抑制钠-葡萄糖协同转运蛋白（SGLT1/SGLT2）已被提议作为一种新型糖尿病治疗策略，该蛋白在肾脏和/或胃肠道葡萄糖吸收中起关键作用。因此，在糖尿病新药研发中，针对SGLT1/SGLT2的化合物筛选和专利申请变得更为重要。几家公司正在开发SGLT抑制剂，其中一些目前正处于临床开发的不同阶段。处于研发阶段的一些分子，包括达格列净、卡格列净、ASP1941、BI10773、LX4211、RG7201和TS071，正处于药物开发的不同阶段。本专利综述展示了在过去十年中，在各制药公司的积极参与下，SGLT抑制剂开发所取得的总体进展。预计这类药物将对糖尿病领域产生重大影响，并有望成为重磅炸弹药物。
